Русский / English
Enter the query
Events
Press Center
phone: +7 495 785 29 07
fax: +7 499 230 32 94
press@interros.ru
Contacts
Calendar
prev January 2018
Mon Tue Wed Thu Fri Sat Sun
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31
30.06.2014
Regular delivery of short-lived isotopes to Krasnoyarsk became possible because Iterport's operator has a license from Atomnarzor. According to classification of International Air Transport Association(IATA), such shipments belong to danger class 7 and require special care and provisional safety measures.
More Topics Interport
21.05.2014
OJSC MMC Norilsk Nickel, the world’s largest nickel and palladium producer, announces that through its Australian subsidiaries, Norilsk Nickel Avalon Pty Ltd and Norilsk Nickel Cawse Pty Ltd, it has entered into definitive agreements to sell its Avalon and Cawse nickel assets currently held in care and maintenance in Western Australia to Wingstar Investments Pty Ltd (“Wingstar”) a resource focused investment company with mining and exploration tenements in Western Australia.
More Topics Norilsk Nickel
15.05.2014
Regional program for cargo transportation to Northern territories has started in March, 2014 and is executed via Il-62M with cargo capacity of 40 tons, which helps, in comparison to passenger planes, transfer nonstandard and bulky cargo to Norilsk. Telemetric equipment for Severo-Paiyakhskoe field counts as bulky cargo and is made as two cylinders with special equipment inside, each 9,5 meters long and with combined weight of more than 2 tons.
More Topics Interport
12.05.2014
The immunobiological production unit of NPO Petrovax Pharm, a Russian pharmaceutical company, has produced more than 2.5 mln doses of Prevenar 13, a 13-valent conjugate pneumococcal vaccine, in easy to use disposable auto injectors. More than 5 mln doses are planned to be produced by the end of 2014.
More Topics Petrovax Pharm
26.03.2014
On March 26, 2014, NPO Petrovax Pharm ran a media tour for key business and industry journalists at the Company's production site in the Podolsk District of Moscow Region. The journalists were taken on a tour around the unique facility where 13-valent conjugate pneumococcal vaccine is produced.
More Topics Petrovax Pharm